Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Castle Biosciences, Inc. - SIC # 8081 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CSTL
Nasdaq
8081
castlebiosciences.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Castle Biosciences, Inc.
New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
- Sep 15th, 2026 5:00 am
JAAD Publication Shows Improved Performance of DecisionDx®-SCC
- Sep 9th, 2026 2:30 pm
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
- Aug 28th, 2026 10:00 am
Castle Biosciences (CSTL) Rallies On Earnings Optimism, Is The Stock Still Cheap?
- Aug 26th, 2026 7:10 pm
Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?
- Aug 25th, 2026 7:55 am
Castle Biosciences to Participate in Upcoming Investor Conferences
- Aug 20th, 2026 5:00 am
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
- Aug 17th, 2026 5:00 am
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
- Aug 12th, 2026 11:01 pm
Castle Biosciences, Inc. Q2 2026 Earnings Call Summary
- Jul 31st, 2026 6:30 am
Castle Biosciences Inc (CSTL) (Q2 2026) Earnings Call Highlights: Revenue Surges 20% to $103. ...
- Jul 30th, 2026 11:03 pm
Castle Biosciences Q2 Earnings Call Highlights
- Jul 30th, 2026 4:04 pm
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
- Jul 30th, 2026 4:00 pm
Castle Biosciences Reports Second Quarter 2026 Results
- Jul 30th, 2026 2:05 pm
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
- Jul 22nd, 2026 5:00 am
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
- Jul 14th, 2026 2:30 pm
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
- Jul 9th, 2026 5:00 am
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down
- Jun 26th, 2026 4:07 am
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
- Jun 25th, 2026 2:30 pm
Scroll